This project aims to develop Conjugated Antibodies-Degraders specific for the treatment of triple-negative breast cancer (TNC), with a comparative oncology approach. By selecting a CMTN-specific PROTAC and combining it with an anti-TROP-2 sdAb, we aim to improve the delivery and effectiveness of treatment. We will validate these DACs by evaluating their efficacy in xenograft models, paving the way for future clinical studies.